Description: Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Home Page: www.aurabiosciences.com
AURA Technical Analysis
85 Bolton Street
Cambridge,
MA
02140
United States
Phone:
617 500 8864
Officers
| Name | Title |
|---|---|
| Dr. Elisabet de los Pinos Ph.D. | Founder, CEO, Pres & Director |
| Ms. Julie B. Feder | CFO, Sec. & Treasurer |
| Dr. Cadmus Collins Rich CPE, M.B.A., M.D., MBA | Chief Medical Officer and Head of R&D |
| Dr. Mark A. De Rosch Ph.D. | Chief Operating Officer |
| Mr. Paulo Carvalho | VP of Technical Operations |
| Mr. Joseph Lyons | VP of HR |
| Ms. Michele Keough M.B.A. | Sr. VP of Project Management and Device Supply Chain |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.8729 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-10-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 52 |